Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
Agency for Care Effectiveness (ACE)
Record ID 32018005598
English
Details
Project Status:
Completed
Year Published:
2024
URL for published report:
https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/details/pembrolizumab-for-treating-high-risk-early-stage-triple-negative-breast-cancer
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Singapore
MeSH Terms
- Breast Neoplasms
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Triple Negative Breast Neoplasms
Contact
Organisation Name:
Agency for Care Effectiveness (ACE)
Contact Address:
Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
ACE_HTA@moh.gov.sg
Contact Email:
ACE_HTA@moh.gov.sg
Copyright:
Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.